My ePortfolio Register   

neoMONARCH: CDK inhibition for HR positive, HER negative breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.12.16
Views: 2332
Rating:

Dr Sara Hurvitz - Ronald Reagan UCLA Medical Center, Los Angeles, USA

Dr Hurvitz speaks with ecancertv at SABCS 2016 about the outcomes of the neoMONARCH trial of abemaciclib, a CDK 4/6 inhibitor, in combination with anastrozole for women with HR positive breast cancer.

The study found that, alone or with anastrozole, abemaciclib induced significantly greater cell cycle arrest, defined by reduced Ki67 expression.

These results were first presented at a press conference session, with video available here.

Dr Hurvitz spoke more on CDK4/6 inhibition at an ecancer symposium in Copenhagen, here.

Supported by a grant from Pfizer Inc.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence